Navigation Links
ADVENTRX Announces Further Cost-Cutting Measures
Date:3/20/2009

SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that, effective April 3, it will reduce its full-time workforce to five employees and will discontinue substantially all of its development activities and fundamental business operations to provide additional time to consummate a strategic transaction or otherwise obtain financing. ADVENTRX's remaining employees, which will consist of its Chief Business Officer and Senior Vice President, its General Counsel, its Senior Vice President of Operations, its Vice President of Regulatory Affairs and Quality and its Manager of Accounting, will focus their efforts primarily on continuing to evaluate and execute strategic options.

"Along with the reductions we implemented in October 2008 and January 2009, and our prior cost-containment measures, the changes we announce today will extend our cash cliff and increase the opportunity for us to close a strategic transaction with one of the parties with whom we currently are in discussions or another company we identify in the future," said Brian M. Culley, ADVENTRX's Chief Business Officer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates are designed to improve the safety and commercial potential of existing cancer treatments. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. More information can be found on ADVENTRX's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX caution
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Provides Update on Strategic Transaction Process
2. ADVENTRX Announces Further Cost-Cutting Measures
3. ADVENTRX Exploring Strategic Options
4. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
5. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
6. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. ADVENTRX Settles Dispute With Former Licensee
9. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. ADVENTRX Appoints Vice President of Manufacturing
11. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... ... and Analyst deliver expanded processing and reporting functionalities. , ... Basel, Switzerland and Lexington, MA ... silico solutions for pharmaceutical R&D and related life sciences, today announced the release ...
... , , , , ... makers of the patented probiotic strain GanedenBC30(R) , today ... The new thin strip product is the latest in a number of ... , , The recent popularity of thin strips as ...
... , BASKING RIDGE, N.J., Sept. ... development of antithrombotic aptamers with active control agents, announced today ... at the BioPharm America Conference 2009 in San Francisco, CA ... Courts, presentation will include an overview of the Company,s pipeline ...
Cached Biology Technology:Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Future Outlook For Biometrics Revenue and Profit Growth, ... (OTC Bulletin Board: BKYI), a leader in wireless ... its,financial results for the third quarter ended September ... for the three months ended,September 30, 2007 was ...
... Nov. 14 The U.S. Department of Homeland,Security (DHS) ... its,biometrics-at-sea program has been a success and accomplished its ... biometric data from,1,368 migrants, prosecuted 90 of those migrants, ... 50 percent in the waters between Puerto Rico,and the ...
... test may be a new biomarker to identify patients with ... researchers report today in the New England Journal of Medicine. ... closer to a treatment for the nations 2.5 million asthmatics ... to treat, the researchers say. The studies were done ...
Cached Biology News:BIO-key Reports Third Quarter 2007 Results 2BIO-key Reports Third Quarter 2007 Results 3BIO-key Reports Third Quarter 2007 Results 4BIO-key Reports Third Quarter 2007 Results 5Biometrics Help Identify, Apprehend and Deter Illegal Migrants 2Yale discovery suggests protein may play a role in severe asthma 2
Rat monoclonal [HEK/1/85a] to CCR5 ( Abpromise for all tested applications). entrezGeneID: 1234 SwissProtID: P51681...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
mCD-1 10 transcription reactions...
Biology Products: